As Per the Report Published on June 2018 by Geon Technology Inc., this has been Proven that Cell Transfection is Used for Recombinant Protein Production

Synthetic biology is a new era of biology which incorporates the engineering principle to biology. Synthetic biology involves the chemical synthesis of DNA by combining the knowledge of genomics so as to reassemble the DNA genomes. The synthetic biology that sequences into the new genes involves genetic engineering, which incorporates the transfection method, among others. As the demand of synthetic biology products is increasing worldwide, the use of transfection products is also increasing.        

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-transfection-market

Global transfection market is expected to reach USD 1,927.11 million by 2028 from USD 936.21 million in 2020 growing with the CAGR of 9.6% in the forecast period of 2021 to 2028. The demand for transfection has been increased in both developed and developing countries and the reason behind this is the increasing occurrence of chronic diseases. The transfection market is growing due to growing demand for chimeric genes and biopharmaceuticals' utilization in the production of proteins. The market will grow in the forecast period due to the exploration of emerging markets, strategic initiatives by market players, and increasing government support.            

Increasing occurrence of chronic diseases enhance the demand for the effective treatment options such as gene therapy across the world will drive the market's growth rate

The increasing cases of chronic diseases such as COVID-19 have led to the discovery of effective gene therapy product, which can replace the defective gene with that of the correct gene. Transfection method is widely used for gene therapy, among others. As the demand of effective and accurate treatment is increasing worldwide, the demand of gene therapy and transfection method is also increasing. Moreover, several undergoing researches proving gene therapy has the potential for chronic disease treatment is also increasing its demand among physicians and patients. This thus signifies that the rise in chronic disease prevalence is a driver for the transfection market growth.

Report Scope and Market Segmentation

Segment Analysis:

Global transfection market is categorized into ten notable segments which are based on type, methods, CRISPR transfection methods, products, organism, types of molecule, application, stage, end user, and distribution channel.

• On the basis of type, the global transfection market is segmented into transient transfection, stable transfection. In 2021, transient transfection segment is expected to dominate the market with 66.2% market share as the high copy number of the transfected genetic material leads to high levels of expressed protein within the period that it exists in the cell. This means the transfected cells can be rapidly concerted to large quantities of protein in 3-7 days from cloned genes. 
• On the basis of methods, the global transfection market is segmented into non-viral methods, viral methods. In 2021, non-viral methods segment is expected to dominate the market with 80.8% market share as the success rates are high and these methods work well for cells cultured on flat dishes. The reagents used in non-viral methods such as lipofectamine and are easily available and inexpensive making them the ideal choice for transfection processes.
• On the basis of CRISPR transfection methods, the global transfection market is segmented into non-viral methods, viral methods. In 2021, non-viral methods segment is expected to dominate the market with 66.1% market share as it provides with the high transfection efficiency and these methods work well for cells cultured on flat dishes.
• On the basis of products, the global transfection market is segmented into reagent & kits, instruments, software. In 2021, reagent & kits segment is expected to dominate the market with 75.5% market share as they are used to enhance the efficacy of transfection process in genetic experiments, allowing for substantial research to be conducted in the fields of applied gene therapies and the synthetic biology.  
• On the basis of organism, the global transfection market is segmented into mammalian cells, plants, fungi, virus, and bacteria. In 2021, mammalian cells segment is expected to dominate the market with 60.7% market share as mammalian cell transfection is a technique commonly used to express exogenous DNA or RNA in a host cell line using many different ways.  
• On the basis of types of molecule, the global transfection market is segmented into plasmid DNA , small interfering RNA (siRNA), proteins, DNA oligonucleotides, ribonucleoprotein complexes (RNPs), others. In 2021, plasmid DNA segment is expected to dominate the market with 40.5% market share as classic transfection technologies have initially been developed for introducing plasmid DNA into cells, and even today it is the most common vector for transfection. 
• On the basis of application, the global transfection market is segmented into in vitro application, in vivo application, bioproduction, others. In 2021, in vitro application segment is expected to dominate the market with 70.0% market share as it involves delivery of cargo molecules (such as nucleic acids – DNA or RNA) into cultured cells which plays a crucial role in research as well as commercial production of molecules.
• On the basis of stage, the global transfection market is segmented into research, preclinical, clinical phases, and commercial. In 2021, research segment is expected to dominate the market with 66.7% market share primarily with the increasing demand for gene expression across synthetic biology industry, agriculture and other applications. The need to enhance the scale of production across the aforementioned application requires research which is augmenting the market for transfection.
• On the basis of end user, the global transfection market is segmented into biopharma, contract research organizations (CROs), contract manufacturing organization/ contract development and manufacturing organization (CMOs/CDMOs), academia, hospitals, clinical labs. In 2021, biopharma segment is expected to dominate the market with 64.2% market share because of the need to improve efficiency & speed for production of desired cells. Biopharma industry utilizes transfection process for academic research as well as commercial production to develop cost effective methods for producing desired proteins to support preclinical and clinical evaluations of potential therapeutics. 

The biopharma segment will dominate the end user segment of the transfection market

The biopharma segment will emerge as the dominating segment end user segment. This is because of the growing number of biopharmaceutical industries in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

• On the basis of distribution channel, the global transfection market is segmented into direct tender, retail sales, others. In 2021, direct tender segment is expected to dominate the market with 84.2% market share as it is the primary source of procurement across end users. Biopharma companies and research groups tend to prefer direct tenders as the more reliable and cost-effective distribution channel.

The direct tender segment will dominate the distribution channel segment of the transfection market

The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players         

Data Bridge Market Research recognizes the following companies as the market players in market: Mirus Bio LLC. (U.S.), Promega Corporation (U.S.), Polyplus Transfection (France), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Lonza (Switzerland), MaxCyte, Inc. (U.S.), Altogen Biosystems (U.S.), SBS Genetech (China), FUJIFILM Irvine Scientific (U.S.), Avanti Polar Lipids (U.K.), PerkinElmer chemagen Technologie GmbH (Germany), Cytiva (U.S.), Geno Technology Inc. (U.S.), R&D Systems, Inc. (U.S.), Takara Bio Inc. (Japan), Thermofisher Scientific Inc. (U.S.), Roche Molecular Systems, Inc. (U.S.), QIAGEN (Germany), OriGene Technologies, Inc. (U.S.).

Market Development

• In May 2019, Altogen Biosystems launched GMP Grade Liver Targeted Transfection Reagent for the in vivo delivery of biomolecules involving miRNA, siRNA, mRNA, plasmid, DNA small proteins, among others. This product has enhanced the targeted delivery of gene and oligonucleotides therapy for liver cancer treatment. This product launched allowed the company to boost its revenue by bolstering the transfection product portfolio.
• In July 2019, Mirus Bio LLC. Launched new quality tested product that is TransIT-VirusGEN SELECT Transfection Reagent indicated for efficient DNA delivery so as to product large scale and high-titer viral vectors. This reagent has the capacity to enhance the delivery of packaging and transfer vector DNA to adherent HEK 293 cell types and DNA suspensions. This product launch enhanced the company's product portfolio and boosted the company's revenue.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

As per Data Bridge Market Research analysis:

North America is the dominant region in transfection market during the forecast period 2021 - 2028

North America region holds the largest share in the global transfection market and U.S. is dominating in the region due to large number of companies and high focus on genetic research & protein production.

Asia-Pacific is estimated to be the fastest-growing region in transfection market the forecast period 2021 - 2028

Asia-Pacific is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing genetic research in the region. China is leading the growth of the Asia-Pacific market and transient transfection segment is dominating in this country due to higher application transient gene expression.    

COVID-19 Impact

The rapid global spread of this virus resulted in a significant number of fatalities. The World Health Organization (WHO) declared COVID-19 a global pandemic in March 2020 and advised strict action to stop the disease's spread. Since then, the pandemic has slowed down healthcare industry growth and hampered the supply chain. However, high demand for transfection drugs presented numerous opportunities ahead of manufacturers for COVID-19 management drugs. In addition, high demand for vaccine and treatment possibilities boosted the growth of pharmaceutical and biotechnology industries.

For more detailed information about the transfection market, visit: https://www.databridgemarketresearch.com/reports/global-transfection-market